Business Wire

Western Union Highlights ESG Progress and Recognitions Received

29.6.2022 15:00:00 EEST | Business Wire | Press release

Share

The Western Union Company (NYSE: WU) today released its 2021 Environmental, Social and Governance (ESG) Report, spotlighting the Company’s ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005138/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Western Union's 2021 ESG report spotlights the Company’s ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.(Photo: Business Wire)

“People are drawn to work for and do business with companies that make an impact,” said Devin McGranahan, Chief Executive Officer. “This year’s report shows that Western Union continues to make solid progress on our ESG journey, which in turn enables us to effect even more positive change in the communities we serve. I’m proud to work with colleagues who bring their best every day to improve the lives of our customers and communities around the world.”

2021 ESG Highlights

Western Union’s ESG strategy is focused on efforts and areas where the Company can make meaningful impact, including:

  • Furthering economic prosperity: The Company launched a digital banking platform in Germany and Romania, combining money transfer, a multi-currency account and debit card. Western Union believes offering people simple, trusted solutions via digital and retail access points creates pathways for long-term economic success.
  • Promoting the integrity of money movement: Western Union also continued progress on our commitment to money movement that is safe, secure and built on a foundation of integrity. While third-party data show the rate of fraudulent activity across the financial industry is increasing, in 2021 our Company’s reported consumer fraud globally decreased by 10% and we prevented approximately $1.9 billion in fraudulent transactions. These efforts were supported by fraud prevention messages that reached consumers through 121 million consumer fraud touches, a 97% increase over 2020.1
  • Advancing diversity, equity, and inclusion: Another key area of focus for the Company in 2021 was advancing diversity, equity and inclusion (DEI). In 2021, Western Union developed a DEI strategy focused on hiring, development, promotion, retention and cultural change. DEI milestones include:
    • A newly formed DEI program office, naming a Chief Diversity and Talent Officer, a specialized diversity recruiting lead and a full-time DEI program lead; and
    • Achieving gender pay equity globally and racial/ethnicity pay equity in the US.

This year also marks the first time Western Union has disclosed our Company’s Scope 1 and 2 greenhouse gas (GHG) emissions.

Increased Recognition

The Company also reported recognitions for its ESG efforts, including:

  • Recognized as one of the World’s Most Ethical Companies® for the first time;
  • Bloomberg’s Gender Equality Index for the third consecutive year;
  • JUST Capital’s Top 100 Companies Supporting Healthy Families and Communities; and
  • Human Rights Campaign’s Best Place to Work for LGBTQ+ Equality.

For more information and additional details related to our 2021 progress, and to download Western Union’s 2021 Environmental, Social and Governance (ESG) Report, click here.

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect consumers, businesses, financial institutions, and governments through one of the world’s widest reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and a substantial global network of retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com.

________________________________

1. Consumer Fraud Awareness Touches are derived from metrics tracked across various platforms, including paid media ads, social media (Facebook, Twitter, YouTube, Community Management), outreach attendees and wu.com/fraudawareness visits. Each platform may have a unique method for quantifying individuals who have consumed anti-fraud content, based on reach, impressions, views, visits and/ or received physical materials. Given that consumers may engage with our content through multiple channels, each “touch” may not be a unique consumer.

WU-G

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Claire Treacy
Claire.Treacy@westernunion.com

Investor Relations:
Tom Hadley
WesternUnion.IR@westernunion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye